Skip to main content

Steinhart Richard I's Form 4 filing

BioXcel Therapeutics, Inc. (BTAIQ) · filed Oct 3, 2024

Accession no.
0001104659-24-106061
Filed
Oct 3, 2024
Trade date
Sep 17-Oct 3, 2024
Filing delay
16 daysLate
Rule 10b5-1 plan
Checked

This filing lists 2 non-derivative transactions. Open-market sales total $3.95K. It was filed 16 days after the trade, past the 2-business-day deadline.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Steinhart Richard ICIK 0001293789Officer (Chief Financial Officer)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Sep 17, 2024Common StockAGrant or awardAcquired+21,250–F1–27,454Direct
Oct 3, 2024Common StockSSaleDisposed−7,175$0.55F3−$3,946.2520,279Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

The Issuer previously granted the Reporting Person an award of restricted stock units that would vest based on the Issuer's satisfaction of certain performance objectives and subject to the Reporting Person's continued service with the Issuer through October 1, 2024 (the "PSUs"). On September 17, 2024, the Compensation Committee of the Issuer's Board of Directors determined that performance conditions with respect to 21,250 PSUs had been satisfied and 21,250 shares of common stock became issuable to the Reporting Person on October 1, 2024.

Referenced by the price of 1 transaction in Table I.

F3

The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $0.5500 to $0.5515. The Reporting Person undertakes to provide upon request the Securities and Exchange Commission staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)